Authors:
Xie, XM
Zhao, XQ
Liu, YF
Young, CYF
Tindall, DJ
Slawin, KM
Spencer, DM
Citation: Xm. Xie et al., Robust prostate-specific expression for targeted gene therapy based on thehuman kallikrein 2 promoter, HUM GENE TH, 12(5), 2001, pp. 549-561
Authors:
Leventis, AK
Shariat, SF
Kattan, MW
Butler, EB
Wheeler, TM
Slawin, KM
Citation: Ak. Leventis et al., Prediction of response to salvage radiation therapy in patients with prostrate cancer recurrence after radical prostatectomy, J CL ONCOL, 19(4), 2001, pp. 1030-1039
Citation: Ak. Leventis et al., Local recurrence after radical prostatectomy: Correlation of US features with prostatic fossa biopsy findings, RADIOLOGY, 219(2), 2001, pp. 432-439
Authors:
Gore, JL
Shariat, SF
Miles, BJ
Kadmon, D
Jiang, N
Wheeler, TM
Slawin, KM
Citation: Jl. Gore et al., Optimal combinations of systematic sextant and laterally directed biopsiesfor detection of prostate cancer, J UROL, 165(5), 2001, pp. 1554-1559
Authors:
Shariat, SF
Desai, S
Song, WT
Khan, T
Zhao, J
Nguyen, C
Foster, BA
Greenberg, N
Spencer, DM
Slawin, KM
Citation: Sf. Shariat et al., Adenovirus-mediated transfer of inducible caspases: A novel "death switch"gene therapeutic approach to prostate cancer, CANCER RES, 61(6), 2001, pp. 2562-2571
Citation: Xm. Xie et al., Adenovirus-mediated tissue-targeted expression of a Caspase-9-based artificial death switch for the treatment of prostate cancer, CANCER RES, 61(18), 2001, pp. 6795-6804
Authors:
Leventis, AK
Shariat, SF
Kattan, MW
Butler, EB
Wheeler, TM
Slawin, KM
Citation: Ak. Leventis et al., Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy (vol 18, pg 1039, 2001), J CL ONCOL, 19(7), 2000, pp. 2109-2109
Authors:
Leventis, AK
Miles, BJ
Gonzales, ET
Slawin, KM
Citation: Ak. Leventis et al., Diagnosis and management of incidental ureterocele during the treatment ofclinically localized prostate cancer, WORLD J URO, 18(6), 2000, pp. 444-448
Authors:
Mikolajczyk, SD
Millar, LS
Marker, KM
Wang, TJ
Rittenhouse, HG
Marks, LS
Slawin, KM
Citation: Sd. Mikolajczyk et al., Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia, PROSTATE, 45(3), 2000, pp. 271-276
Authors:
Shariat, SF
Bergamaschi, F
Adler, HL
Nguyen, C
Kattan, MW
Wheeler, TM
Slawin, KM
Citation: Sf. Shariat et al., Correlation of preoperative plasma IGF-I levels with pathologic parametersand progression in patients undergoing radical prostatectomy, UROLOGY, 56(3), 2000, pp. 423-429
Authors:
Catalona, WJ
Southwick, PC
Slawin, KM
Partin, AW
Brawer, MK
Flanigan, RC
Patel, A
Richie, JP
Walsh, PC
Scardino, PT
Lange, PH
Gasior, GH
Loveland, KG
Bray, KR
Citation: Wj. Catalona et al., Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, UROLOGY, 56(2), 2000, pp. 255-260
Authors:
Catalona, WJ
Partin, AW
Slawin, KM
Naughton, CK
Brawer, MK
Flanigan, RC
Richie, JP
Patel, A
Walsh, PC
Scardino, PT
Lange, PH
deKernion, JB
Southwick, PC
Loveland, KG
Parson, RE
Gasior, GH
Citation: Wj. Catalona et al., Percentage of free PSA in black versus white men for detection and stagingof prostate cancer: A prospective multicenter clinical trial, UROLOGY, 55(3), 2000, pp. 372-376
Authors:
Mikolajczyk, SD
Millar, LS
Wang, TJ
Rittenhouse, HG
Wolfert, RL
Marks, LS
Song, WT
Wheeler, TM
Slawin, KM
Citation: Sd. Mikolajczyk et al., "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia, UROLOGY, 55(1), 2000, pp. 41-45
Authors:
Wang, TJ
Slawin, KM
Rittenhouse, HG
Millar, LS
Mikolajczyk, SD
Citation: Tj. Wang et al., Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies, EUR J BIOCH, 267(13), 2000, pp. 4040-4045
Authors:
Mikolajczyk, SD
Millar, LS
Wang, TJ
Rittenhouse, HG
Marks, LS
Song, WT
Wheeler, TM
Slawin, KM
Citation: Sd. Mikolajczyk et al., A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue, CANCER RES, 60(3), 2000, pp. 756-759
Authors:
Slawin, KM
Shariat, SF
Nguyen, C
Leventis, AK
Song, WT
Kattan, HW
Young, CYF
Tindall, DJ
Wheeler, TM
Citation: Km. Slawin et al., Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein, CANCER RES, 60(24), 2000, pp. 7142-7148
Authors:
Southwick, PC
Catalona, WJ
Partin, AW
Slawin, KM
Brawer, MK
Flanigan, RC
Patel, A
Richie, JP
Walsh, PC
Scardino, PT
Lange, PH
Gasior, GH
Parson, RE
Loveland, KG
Citation: Pc. Southwick et al., Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial, J UROL, 162(4), 1999, pp. 1346-1351